Clinical Trial Update: A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism [Phase 1]

View source ↗

Summary

Phase 1 mass-balance study of [14C] MT1013 in hemodialysis patients with secondary hyperparathyroidism is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• MT1013

Snippet

Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Conditions: Hemodialysis Subjects With Secondary Hyperparathyroidism | Phase 1 | Status: RECRUITING